Treatment Approach for Pulmonary Hypertension with Enlarged Pulmonary Artery

Initial Diagnostic Evaluation

Right heart catheterization is essential to confirm the diagnosis of pulmonary hypertension, establish the specific classification, determine severity, and guide therapy, as recommended by the American College of Chest Physicians 1, 2
Vasoreactivity testing using short-acting agents is mandatory for patients with idiopathic PAH to identify potential responders to calcium channel blockers, according to the American College of Chest Physicians 1, 3
Ventilation-perfusion scanning should be performed to rule out chronic thromboembolic pulmonary hypertension (CTEPH), as suggested by the American College of Chest Physicians 1, 2

High-dose calcium channel blockers are the first-line therapy for patients demonstrating a favorable acute response to vasodilator testing, as recommended by the American College of Chest Physicians 1, 4
Intravenous prostacyclin analogues (epoprostenol) are recommended for high-risk patients, as they have demonstrated survival benefits, according to the American Heart Association 5, 2

Diuretics are recommended for managing fluid overload with careful monitoring of electrolytes and renal function, as suggested by the European Society of Cardiology 3, 2
Oxygen supplementation should be used as needed to maintain arterial oxygen saturations >90%, according to the European Society of Cardiology 6, 2

Regular follow-up assessments every 3-6 months in stable patients are recommended, as suggested by the American College of Chest Physicians 2
Treatment goal is to achieve and maintain low-risk status, including a 6-minute walk distance >440m, according to the American College of Chest Physicians 3

Patients with PAH should be managed at specialized centers with expertise in pulmonary hypertension, as recommended by the American Heart Association 5, 2
Patients with severe disease who fail to respond to maximal medical therapy should be referred for lung transplantation evaluation, according to the American College of Chest Physicians 1, 2

Classification according to the clinical guidelines is crucial to distinguish Group 1 PAH from other forms of pulmonary hypertension, as each requires a unique management approach, as recommended by the National Institute for Health and Care Excellence (NICE) 7
Combination therapy may be appropriate for patients not responding adequately to monotherapy, as suggested by the European Society of Cardiology 7

Regular follow-up is essential to confirm sustained response to calcium channel blockers, as recommended by the American College of Cardiology 8
Oral therapies including phosphodiesterase-5 inhibitors (sildenafil) are recommended as initial therapy for WHO Functional Class II patients, as suggested by the American Thoracic Society 8
Endothelin receptor antagonists may also be considered as initial therapy for WHO Functional Class II patients, as recommended by the European Respiratory Society 8
Consider either oral therapies or prostacyclin analogues depending on risk assessment for WHO Functional Class III patients, as suggested by the American College of Chest Physicians 8

Adjustments to therapy should be made based on clinical response and hemodynamic parameters, as recommended by the International Society for Heart Research 8